147 related articles for article (PubMed ID: 29698572)
1. Attenuated Salmonella VNP20009 mutant (ΔhtrA) is a promising candidate for bacteria-mediated tumour therapy in hosts with TNFR1 deficiency.
Xu W; Zhou T; Zhou J; Qiang Z; Zhang J; Hua Z
Lett Appl Microbiol; 2018 Jul; 67(1):97-103. PubMed ID: 29698572
[TBL] [Abstract][Full Text] [Related]
2. The genes slyA, STM3120 and htrA are required for the anticancer ability of VNP20009.
Zhang X; Xu Q; Yang L; Lai Y; Zhang Z; Han C; Jiang C; Li J; Shi Y; Hua ZC
Oncotarget; 2016 Dec; 7(49):81187-81196. PubMed ID: 27835896
[TBL] [Abstract][Full Text] [Related]
3. Oral delivery of tumor-targeting Salmonella exhibits promising therapeutic efficacy and low toxicity.
Chen G; Wei DP; Jia LJ; Tang B; Shu L; Zhang K; Xu Y; Gao J; Huang XF; Jiang WH; Hu QG; Huang Y; Wu Q; Sun ZH; Zhang JF; Hua ZC
Cancer Sci; 2009 Dec; 100(12):2437-43. PubMed ID: 19793349
[TBL] [Abstract][Full Text] [Related]
4. [Anti-tumor effect and impact on tumor immune microenvironment of tumor-targeted Salmonella VNP20009].
Han YH; Lai XH; Le ZW; Hua ZC
Yao Xue Xue Bao; 2016 Sep; 51(9):1417-22. PubMed ID: 29924525
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effect of VNP20009, an attenuated Salmonella, in murine tumor models.
Luo X; Li Z; Lin S; Le T; Ittensohn M; Bermudes D; Runyab JD; Shen SY; Chen J; King IC; Zheng LM
Oncol Res; 2001; 12(11-12):501-8. PubMed ID: 11939414
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the selective targeting efficacy of Salmonella typhimurium A1-R and VNP20009 on the Lewis lung carcinoma in nude mice.
Zhang Y; Zhang N; Zhao M; Hoffman RM
Oncotarget; 2015 Jun; 6(16):14625-31. PubMed ID: 25714030
[TBL] [Abstract][Full Text] [Related]
7. Chloroquine enhanced the anticancer capacity of VNP20009 by inhibiting autophagy.
Zhang X; Xu Q; Zhang Z; Cheng W; Cao W; Jiang C; Han C; Li J; Hua Z
Sci Rep; 2016 Jul; 6():29774. PubMed ID: 27412722
[TBL] [Abstract][Full Text] [Related]
8. Tumor-targeting Salmonella typhimurium, a natural tool for activation of prodrug 6MePdR and their combination therapy in murine melanoma model.
Chen G; Tang B; Yang BY; Chen JX; Zhou JH; Li JH; Hua ZC
Appl Microbiol Biotechnol; 2013 May; 97(10):4393-401. PubMed ID: 22868826
[TBL] [Abstract][Full Text] [Related]
9. Application of genetically engineered Salmonella typhimurium for interferon-gamma-induced therapy against melanoma.
Yoon W; Park YC; Kim J; Chae YS; Byeon JH; Min SH; Park S; Yoo Y; Park YK; Kim BM
Eur J Cancer; 2017 Jan; 70():48-61. PubMed ID: 27883926
[TBL] [Abstract][Full Text] [Related]
10. Effect of Salmonella enterica serovar Typhimurium VNP20009 and VNP20009 with restored chemotaxis on 4T1 mouse mammary carcinoma progression.
Coutermarsh-Ott SL; Broadway KM; Scharf BE; Allen IC
Oncotarget; 2017 May; 8(20):33601-33613. PubMed ID: 28431394
[TBL] [Abstract][Full Text] [Related]
11. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium.
Clairmont C; Lee KC; Pike J; Ittensohn M; Low KB; Pawelek J; Bermudes D; Brecher SM; Margitich D; Turnier J; Li Z; Luo X; King I; Zheng LM
J Infect Dis; 2000 Jun; 181(6):1996-2002. PubMed ID: 10837181
[TBL] [Abstract][Full Text] [Related]
12. Salmonella-mediated tumor-targeting TRAIL gene therapy significantly suppresses melanoma growth in mouse model.
Chen J; Yang B; Cheng X; Qiao Y; Tang B; Chen G; Wei J; Liu X; Cheng W; Du P; Huang X; Jiang W; Hu Q; Hu Y; Li J; Hua ZC
Cancer Sci; 2012 Feb; 103(2):325-33. PubMed ID: 22054098
[TBL] [Abstract][Full Text] [Related]
13. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001.
Cunningham C; Nemunaitis J
Hum Gene Ther; 2001 Aug; 12(12):1594-6. PubMed ID: 11529249
[TBL] [Abstract][Full Text] [Related]
14. Oral delivery of tumor-targeting Salmonella for cancer therapy in murine tumor models.
Jia LJ; Wei DP; Sun QM; Huang Y; Wu Q; Hua ZC
Cancer Sci; 2007 Jul; 98(7):1107-12. PubMed ID: 17498202
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic vaccines based on genetically modified Salmonella: a novel strategy in cancer immunotherapy.
Chorobik P; Marcinkiewicz J
Pol Arch Med Wewn; 2011 Dec; 121(12):461-6. PubMed ID: 22129784
[TBL] [Abstract][Full Text] [Related]
16. Improving tumor targeting and therapeutic potential of Salmonella VNP20009 by displaying cell surface CEA-specific antibodies.
Bereta M; Hayhurst A; Gajda M; Chorobik P; Targosz M; Marcinkiewicz J; Kaufman HL
Vaccine; 2007 May; 25(21):4183-92. PubMed ID: 17399861
[TBL] [Abstract][Full Text] [Related]
17. Genetically engineered Salmonella Typhimurium: Recent advances in cancer therapy.
Liang K; Liu Q; Li P; Luo H; Wang H; Kong Q
Cancer Lett; 2019 Apr; 448():168-181. PubMed ID: 30753837
[TBL] [Abstract][Full Text] [Related]
18. Construction of VNP20009: a novel, genetically stable antibiotic-sensitive strain of tumor-targeting Salmonella for parenteral administration in humans.
Low KB; Ittensohn M; Luo X; Zheng LM; King I; Pawelek JM; Bermudes D
Methods Mol Med; 2004; 90():47-60. PubMed ID: 14657558
[No Abstract] [Full Text] [Related]
19. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma.
Toso JF; Gill VJ; Hwu P; Marincola FM; Restifo NP; Schwartzentruber DJ; Sherry RM; Topalian SL; Yang JC; Stock F; Freezer LJ; Morton KE; Seipp C; Haworth L; Mavroukakis S; White D; MacDonald S; Mao J; Sznol M; Rosenberg SA
J Clin Oncol; 2002 Jan; 20(1):142-52. PubMed ID: 11773163
[TBL] [Abstract][Full Text] [Related]
20. Modulation of
Chen J; Qiao Y; Tang B; Chen G; Liu X; Yang B; Wei J; Zhang X; Cheng X; Du P; Jiang W; Hu Q; Hua ZC
Theranostics; 2017; 7(8):2250-2260. PubMed ID: 28740548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
